Research
Print page
Switch language
Rigshospitalet
- a part of Copenhagen University Hospital
Published
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36
Research output: Contribution to journal › Journal article › Research › peer-review
[11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.
| Original language | English |
|---|---|
| Journal | Molecular Imaging and Biology |
| Volume | 15 |
| Issue number | 4 |
| Pages (from-to) | 376-83 |
| Number of pages | 8 |
| ISSN | 1536-1632 |
| DOIs | |
| Publication status | Published - Aug 2013 |
ID: 42576417